Latest News and Press Releases

Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager

WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and...

WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and...

Business combination closed November 13, 2024Raised $10 million of gross proceeds in connection with the business combinationAgreements are in place with Yorkville for up to a $50 million standby...

매사추세츠주 우번 & 뉴욕, Jan. 23, 2024 (GLOBE NEWSWIRE) -- 차세대 항체 치료제를 통해 치명적인 중증 질환에 직면한 인류의 삶을 개선해 나간다는 사명을 갖고 있는 Abpro Corporation (이하 "Abpro")와 특수목적 인수기업인 Atlantic Coastal Acquisition Corp. II (나스닥:...

WOBURN, Mass. and NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Abpro Corporation (“Abpro”), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening...

Preclinical pseudovirus data and structural modeling shows ABP 310 retains activity and potency against the SARS-CoV-2 Omicron variant mutationsABP 310 EUA possible as early as 2022 WOBURN, Mass.,...

Data showed reduction of neovascular lesion formation and vascular leakage in a rodent model of choroidal neovascularizationABP201 performed equally or better than aflibercept in lesion inhibition and...

• Results of this study showed safety and pharmacokinetic data at doses from 4 mg/kg to 60 mg/kg • Phase 2/3 registrational studies have been initiated WOBURN, Mass., Feb. 02, 2021 (GLOBE...

ABP 300 is a novel human antibody therapy that has been shown to neutralize COVID-19 in preclinical in vivo studiesPivotal/Registrational studies will assess safety, tolerability, efficacy, and...